Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, gives an overview of key updates in transplantation for newly diagnosed multiple myeloma as presented at ASH 2020. In particular, Dr Richardson highlights updates from the Phase II FORTE trial (NCT02203643) evaluating carfilzomib (K) plus lenalidomide-dexamethasone (KRd) induction-autologous stem cell transplantation (ASCT) with KRd consolidation, compared to K plus cyclophosphamide-dexamethasone (KCd)-induction-ASCT with KCd consolidation. He also discusses the Phase III EMN02/HO95 trial (NCT01208766) comparing bortezomib-melphalan-prednisone (VMP) versus high-dose melphalan plus single or double ASCT after induction with VMP. Finally, Dr Richardson talks about the long-term follow-up on the IFM 2009 trial (NCT03679351) comparing early versus late ASCT. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

свернуть